COMMUNIQUÉS West-GlobeNewswire

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

11/09/2017 - 09:00

FIT Biotech Oy Company release September 11, 2017 at 10:00 AM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 [...]

Solon Eiendom ASA : Primary insider notification

11/09/2017 - 08:30

(Oslo, Norway, 08 September 2017) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company Hortulan AS) has today bought 133,553 shares in Solon Eiendom ASA at a price of NOK 17.5373 per [...]

Xbrane confirms order of Spherotide to value of SEK 8.5 million and more than 10,000 doses sold

11/09/2017 - 08:00

Press release 2017-09-11 Xbrane has confirmed an additional order of Spherotide from Pooyesh Darou, its partner in the Middle East, to a value of SEK 8.5 million to be delivered in Q4 2017. With this delivery Xbrane [...]

Infant Bacterial Therapeutics announces that top line data demonstrate similar safety and tolerability profile in the active and placebo groups.

11/09/2017 - 08:00

Infant Bacterial Therapeutics and the principal investigator Dr. Josef Neu have made an initial evaluation of the top line data of the Phase II "Randomized, double blind, parallel-group, dose escalation placebo- [...]

SelectMDx Outperforms PCA3 Stratifying Men for mpMRI

11/09/2017 - 07:00

Test Reduces Unnecessary Invasive Procedures NEWS RELEASE IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, September 11, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced results from a retrospective study published [...]

SelectMDx plus performant que PCA3 pour sélectionner les hommes devant passer une IRM-mp

11/09/2017 - 07:00

Le test limite les procédures invasives inutiles COMMUNIQUÉ DE PRESSE IRVINE, CA, et HERSTAL, BELGIQUE - 07:00 CEST, 11 septembre, 2017 - MDxHealth SA (Euronext : MDXH.BR) a annoncé les résultats d'une étude [...]

INNATE PHARMA : New preclinical data further strengthen the rationale of IPH5401 and monalizumab

11/09/2017 - 07:00

ICI conference 2017: NEW PRECLINICAL DATA further strengthen the rationale of IPH5401 AND MONALIZUMAB for cancer treatments and in combination with anti-PD-1/PD-L1 IPH5401, an anti-C5aR antibody, potentially reverses [...]

INNATE PHARMA: nouvelles données précliniques renforçant le rationnel d'IPH5401 et monalizumab

11/09/2017 - 07:00

ConfÉrence ICI 2017 : NOUVELLES donnÉes prÉcliniques RENFORcant le rationnel d'iph5401 et monalizumab dans le traitement du cancer et en combinaison avec des anti-PD-1/PD-L1 En inversant l'immunosuppression dans le [...]

First Patients Enrolled in UK's Early Access to Medicines Scheme for Santhera's Raxone® in Duchenne Muscular Dystrophy (DMD)

11/09/2017 - 07:00

Liestal, Switzerland, September 11, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces enrollment of first DMD patients with respiratory function decline not taking glucocorticoids into UK's Early Access to Medicines [...]

Targovax ASA: Three posters presented at ESMO conference

11/09/2017 - 07:00

Oslo, Norway, 11 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces that three posters [...]

Sanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial

11/09/2017 - 06:58

Sanofi and Regeneron Announce Positive Dupilumab Topline Results From Phase 3 Trial in Uncontrolled Persistent Asthma - Investigational dupilumab reduced severe asthma attacks and improved lung function - Paris, France [...]

Sanofi et Regeneron annoncent les premiers résultats positifs d'une étude de phase 3 consacrée au dupilumab dans le traitement de l'asthme persistant non contrôlé

11/09/2017 - 06:58

Sanofi et Regeneron annoncent les premiers résultats positifs d'une étude de phase 3 consacrée au dupilumab dans le traitement de l'asthme persistant non contrôlé - L'agent expérimental dupilumab a permis de réduire les [...]

Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma

11/09/2017 - 00:05

The three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo[1] Consistent improvement in RFS observed across all pre-specified subgroups, including [...]

Novartis presents new data at EURETINA 2017 confirming Lucentis® efficacy and durability vs aflibercept

09/09/2017 - 11:00

Interim results of the head-to-head RIVAL study confirm strong efficacy and comparable durability versus aflibercept in patients with nAMD Five-year results from the Lucentis LUMINOUS study, the largest ever in retinal [...]

L'Association internationale pour l'étude du cancer du poumon annonce des sélections de rapports pour la 18e Conférence mondiale sur le cancer du poumon

08/09/2017 - 23:41

Des travaux de recherche révolutionnaires mettront en lumière les progrès les plus récents dans l'étude du cancer du poumon DENVER, 2017-09-08 (GLOBE NEWSWIRE) -- L'Association internationale pour l'étude du cancer du [...]

LifeVantage Corporation élargit sa présence mondiale avec une expansion en Allemagne

08/09/2017 - 18:18

Les produits disponibles en Allemagne incluent le Synergizer Nrf2 Protandim® et TrueScience®, la crème antivieillissement pour les soins de la peau de la société SALT LAKE CITY, le 8 septembre 2017 (GLOBE NEWSWIRE) - [...]

PCI Biotech: Capital increase registered and listing of new shares

08/09/2017 - 14:34

Oslo, 8 September 2017 - Reference is made to the stock exchange notice of 5 September 2017 by PCI Biotech Holding ASA (the "Company") in respect of the issuance of 86,500 new shares following exercise of employee share [...]

Information from Infant Bacterial Therapeutics Capital Markets Day 2017

08/09/2017 - 14:33

Infant Bacterial Therapeutics has today, September 8, 2017, hosted a Capital Markets Day for investors, financial analysts and media in Stockholm. The purpose of the Capital Markets Day was to present Infant Bacterial [...]

Inivata: Inivata Announces Appointment of Dr Jamie Platt as Chief Operations Officer

08/09/2017 - 13:30

Inivata Announces Appointment of Dr Jamie Platt as Chief Operations Officer Research Triangle Park, NC and Cambridge, UK, September 8, 2017 -- Inivata , a global clinical cancer genomics company utilizing an industry- [...]